Tianjin Tianyao Pharmaceutical Co (SHSE:600488) Short-Term Debt: ¥88 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600488 Tianjin Tianyao Pharmaceutical Co Ltd SHSE:600488
58 GF Score
Price ¥5.91
GF Value ¥3.57
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Tianjin Tianyao Pharmaceutical Co Short-Term Debt?

Tianjin Tianyao Pharmaceutical Co SHSE:600488 +0.85% 58 Short-Term Debt is ¥88 Mil as of Mar. 2026. GuruFocus rates SHSE:600488 with a GF Score™ of 58/100 and a GF Value™ of ¥3.57 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Tianjin Tianyao Pharmaceutical Co's Short-Term Debt for the quarter that ended in Mar. 2026 was ¥88 Mil.

Tianjin Tianyao Pharmaceutical Co's quarterly Short-Term Debt increased from Sep. 2025 (¥150 Mil) to Dec. 2025 (¥168 Mil) but then declined from Dec. 2025 (¥168 Mil) to Mar. 2026 (¥88 Mil).

Tianjin Tianyao Pharmaceutical Co's annual Short-Term Debt declined from Dec. 2023 (¥270 Mil) to Dec. 2024 (¥109 Mil) but then increased from Dec. 2024 (¥109 Mil) to Dec. 2025 (¥168 Mil).

Tianjin Tianyao Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Tianjin Tianyao Pharmaceutical Co Short-Term Debt Related Terms

Tianjin Tianyao Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Tianjin Tianyao Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Tianyao Pharmaceutical Co Short-Term Debt Chart

Tianjin Tianyao Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 588.63 648.34 270.25 108.58 167.88

Tianjin Tianyao Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 125.71 159.85 149.85 167.88 88.07
SHSE:600488
58GF Score
Tianjin Tianyao Pharmaceutical Co Ltd SHSE:600488
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥88 Mil mean?
Tianjin Tianyao Pharmaceutical Co (SHSE:600488) has a Short-Term Debt of ¥88 Mil as of Mar. 2026.
Is Tianjin Tianyao Pharmaceutical Co's Short-Term Debt too high?
Tianjin Tianyao Pharmaceutical Co's current Short-Term Debt is ¥88 Mil. Overall, Tianjin Tianyao Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Tianyao Pharmaceutical Co's Short-Term Debt compare to ZTS?
Tianjin Tianyao Pharmaceutical Co's Short-Term Debt of ¥88 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Tianjin Tianyao Pharmaceutical Co's current Short-Term Debt is ¥88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Tianyao Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Tianyao Pharmaceutical Co (SHSE:600488) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.57, compared to a current price of ¥5.91 — trading 65.5% above its estimated fair value. The current Short-Term Debt is ¥88 Mil. Tianjin Tianyao Pharmaceutical Co's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Tianjin Tianyao Pharmaceutical Co (SHSE:600488), the current Short-Term Debt is ¥88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianjin Tianyao Pharmaceutical Co (SHSE:600488) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin Tianyao Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥5.91 is trading 65.5% above its estimated GF Value™ of ¥3.57. GuruFocus considers Tianjin Tianyao Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:600488:

  • Short-Term Debt: ¥88 Mil
  • GF Value™: ¥3.57 vs. price of ¥5.91 (65.5% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the SHSE:600488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tianjin Tianyao Pharmaceutical Co Business Description

Address No. 221 Huanghai Road, Tianjin Development Zone, Tianjin, CHN, 300457
Tianjin Tianyao Pharmaceutical Co Ltd is a China-based company engages in the development, manufacture, distribution, and export of pharmaceutical products. Its products include corticosteroids and cardiovascular medicine, dexamethasone, and cortisone acetate.
58GF Score

Get the complete analysis for SHSE:600488

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.91
Price
¥3.57
GF Value